2025-2034 Growth Prospects of the Acromegaly Market: Key Trends and Opportunities Analyzed
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Significant is the Anticipated Growth Rate of the Acromegaly Market from 2025 to 2034?
The market for acromegaly has seen swift expansion in recent years. There is an expected increase from $2.15 billion in 2024 to $2.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 19.6%. Factors such as the rising prevalence of therapeutic treatments for acromegaly, increased awareness of the condition, government initiatives, and the demand for efficacious treatments have contributed to the growth during the historic period.
There is an anticipation for the market size of acromegaly to witness considerable growth over the upcoming years, reaching a value of $4.92 billion in 2029 with a 17.6% compound annual growth rate (CAGR). This expansion forecasted over the period can be credited to investment in research and development programs for acromegaly treatments, heightened screening initiatives, increased healthcare expenditure, and a growing preference for less intrusive treatment choices. Top trends for the anticipated period involve novel acromegaly treatments, introduction of specifically targeted therapies, a robust pipeline of medicinal drugs, advances in treatment strategies, and enhanced tailor-made medicine.
Which Macro and Microeconomic Factors Are Accelerating the Growth of the acromegaly Market?
An increase in hormonal diseases such as diabetes is projected to fuel the acromegaly market’s growth. Known as endocrine disorders, hormonal diseases are health conditions caused by abnormalities in the endocrine system. Diabetes is a prominent hormonal disease. Overproduction of certain hormones, such as growth hormone or cortisol, can lead to acromegaly and other endocrine disorders. Furthermore, excessive growth hormone may compromise insulin synthesis, leading to insulin resistance or type-2 diabetes in approximately 50% of acromegaly patients. The Office for Health Improvement and Disparities reported in March 2024 that from March 2022 to March 2023, the number of type 1 diabetes patients receiving all eight recommended care processes rose by 22%, and the number for type 2 diabetes increased by 21%. During that time, the number of patients achieving target HbA1c levels jumped to 37.9%, the National Diabetes Audit’s highest-ever figure. Therefore, the rise in hormonal disease prevalence is stimulating the acromegaly market growth. The acromegaly market is expected to expand due to the increasing prevalence of genetic abnormalities. These abnormalities, also called genetic defects or disorders, are changes in a person’s genetic code that can lead to unusual characteristics or functions. Overproduction of growth hormone by the pituitary gland, often caused by benign adenomas, can cause acromegaly. These adenomas can occur randomly or be associated with specific genetic conditions. For instance, in February 2022, the World Health Organization stated that birth abnormalities cause 240,000 newborns to die within the first 28 days of life each year and another 170,000 children between 1 month and 5 years old die due to anomalies including heart defects, neural tube defects, and Down syndrome. Thus, the increased prevalence of genetic abnormalities is expected to fuel the acromegaly market’s growth.
Request Your Free Acromegaly Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp
Who Are the Dominant Players Pushing the Boundaries of the Acromegaly Market?
Major companies operating in the acromegaly market are:
• Pfizer Inc._x000D_
• Johnson & Johnson Private Limited_x000D_
• Merck & Co Inc._x000D_
• AbbVie Inc._x000D_
• Bayer AG_x000D_
How Are Market Trends Revolutionizing the Acromegaly Industry in Recent Times?
Leading firms in the acromegaly market are striving to create innovative products and solutions, like generic lanreotide, to advance treatment alternatives and ameliorate patient outcomes. Generic lanreotide is a non-branded version of the drug used for the treatment of acromegaly and specific neuroendocrine tumors. It functions as a somatostatin analog, reducing the secretion of growth hormones and enhancing patient access to effective therapy options. For example, in October 2024, Teva Pharmaceutical Industries Ltd., a pharmaceutical firm from Israel that specializes in generic drugs, introduced the first and exclusive generic edition of the Sandostatin LAR Depot in the United States. The injectable compound, octreotide acetate, is prescribed for acromegaly treatment and severe diarrhoea related to carcinoid syndrome. This new addition makes crucial therapy more accessible for patients necessitating these treatments.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report
What Are the Core Categories and Segments in the Acromegaly Market Driving Demand and Growth?
The acromegaly market covered in this report is segmented –
1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments
5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users
Subsegments:
1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly
2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess
Which Geographic Areas Are Influencing the Growth of the Acromegaly Market?
North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Core Features That Define the Acromegaly Market?
Acromegaly is a rare hormonal disorder that occurs when the pituitary gland, a small gland located at the base of the brain, produces excessive growth hormone. This excess growth hormone leads to the enlargement and thickening of bones and tissues in various body parts, particularly the hands, feet and face.
Browse Through More Similar Reports By The Business Research Company:
Nerve Repair And Regenerative Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report
Neurophysiology Devices And Equipment Global Market Report 2024
Generic Central Nervous System Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
